Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17

被引:37
作者
Simonetti, Sara [1 ]
Russo, Rosa [2 ]
Ciancia, Giuseppe [1 ]
Altieri, Vincenzo [3 ]
De Rosa, Gaetano [1 ,4 ]
Insabato, Luigi [1 ]
机构
[1] Univ Naples Federico 2, Dept Biomorphol & Funct Sci, I-80131 Naples, Italy
[2] San Leonardo Hosp, Operat Unit Pathol, Salerno, Italy
[3] Univ Naples Federico 2, Dept Urol, Naples, Italy
[4] Reg Oncol Hosp, Basilicata Referral Ctr, Pathol & Cytopathol Unit, Potenza, Italy
关键词
chromosome; 17; FISH analysis; HER2/neu; polysomy; transitional cell carcinoma; IN-SITU HYBRIDIZATION; PROTEIN OVEREXPRESSION; TISSUE MICROARRAY; PROGNOSTIC VALUE; URINARY-BLADDER; AMPLIFICATION; CANCER; RECURRENCE; THERAPY; PROGRESSION;
D O I
10.1177/1066896909333415
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study investigates the potential clinical significance of c-erbB-2 gene and chromosome 17 alterations by fluorescence in situ hybridization (FISH) analysis and HER2/neu overexpression by immunohistochemical staining in transitional cell carcinoma (TCC) of urinary bladder correlating the results with tumor stage and grade categories and with clinical behavior. Sixty-three cases of TCC retrieved from the files of 2 institutions were analyzed for chromosome 17 aberrations and c-erbB-2 amplification by FISH analysis and evaluated immunohistochemically for HER2/neu overexpression. Five tumors were G1, 29 intermediate grade (G2), and 29 tumors high grade (G3); 32 tumors had stage Ta, IS tumors T1, and 13 tumors T2. We found polysomy of chromosome 17 in 58.7% of TCC with average chromosome copy number >2.26; increased number of HER2/neu gene copy was observed in 66.7% of tumors. C-erbB-2 amplification occurred in 6.3% of tumors. Immunohistochemically, 60.3% of TCC overexpressed HER2/neu and 39.7% of tumors were negative. All tumors with polysomy showed Simultaneously increase of HER2/neu gene copy number of which 34/37 with protein overexpression. A statistically significant correlation between polysomy of chromosome 17 and tumor stage (P = .0003) and tumor grade (P < .0001) was found; polysomy was not seen in G1 tumors; however, 8/29 G2 tumors and 29/29 G3 tumors revealed polysomy of chromosome 17; in 8/32 Ta tumors, 14/18 T1. and 13/13 of deeply invasive tumors (T2) polysomy 17 was observed. Moreover, it was found that 7 superficial tumors (1 Ta and 6 T1) showed high polysomy with average of chromosome 17 copy number >= 3.76 as observed in all invasive tumors. The data suggest that although HER2/neu amplification, found in high grade and invasive tumors, is a rare event in TCC, polysomy of chromosome 17 is an important factor correlated with tumor stage and grade categories and could be considered a molecular marker of tumor progression with interesting diagnostic implications.
引用
收藏
页码:198 / 205
页数:8
相关论文
共 48 条
  • [31] ULTRASTRUCTURAL-LOCALIZATION OF C-ERBB-2 GENE-PRODUCT IN TRANSITIONAL CELL-CARCINOMA OF THE URINARY-TRACT
    MORIYAMA, M
    MORISHITA, Y
    MORI, S
    AKIYAMA, T
    KATO, T
    [J]. ULTRASTRUCTURAL PATHOLOGY, 1990, 14 (05) : 399 - 405
  • [32] HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: Correlation with oncoprotein expression and conventional pathological parameters
    Cianciulli, AM
    Guadagni, F
    Marzano, R
    Benevolo, M
    Merola, R
    Giannarelli, D
    Marandino, F
    Vocaturo, G
    Mariani, L
    Mottolese, M
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (02) : 265 - 271
  • [33] AMPLIFICATION OF ONCOGENES ERBB-2 (HER-2/NEU), ERBB-1 (HER-1), AND C-MYC OFTEN COMBINES WITH DELETION OF CHROMOSOME-17 SHORT ARM IN HUMAN CARCINOMAS
    IMYANITOV, EN
    CHERNITSA, OI
    NIKIFOROVA, IF
    SEROVA, OM
    SOKOLOV, SI
    LAUR, OA
    TOGO, AV
    KNYAZEV, PG
    [J]. MOLECULAR BIOLOGY, 1993, 27 (04) : 547 - 551
  • [34] Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results.: A further contribution to defining the role of fluorescent in situ hybridization
    Sidoni, A
    Ferri, I
    Cavaliere, A
    Bellezza, G
    Scheibel, M
    Bucciarelli, E
    [J]. ANTICANCER RESEARCH, 2006, 26 (3B) : 2333 - 2337
  • [35] An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan
    Fong, Yao
    Chou, Shan-Ju
    Hung, Kai-Feng
    Wu, Ho-Tai
    Kao, Shou-Yen
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2008, 71 (03) : 123 - 127
  • [36] Quantitative mast cell analysis and hormone receptor study (ER, PR and HER2/neu) in invasive carcinoma of breast
    Pyla, Rama D.
    Potekar, R. M.
    Patil, Vijayalaxmi S.
    Reddy, Anil K.
    Sathyashree, K. V.
    [J]. INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2020, 63 (02) : 200 - 204
  • [37] c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients
    Riou, G
    Mathieu, MC
    Barrois, M
    Le Bihan, ML
    Ahomadegbe, JC
    Bénard, J
    Lê, MG
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 95 (04) : 266 - 270
  • [38] HER2/CHR 17 tissue microarray chromogenic in situ hybridization analysis in colon adenocarcinoma: multiple gene signals vs protein expression
    Fotiades, Panagiotis P.
    Tsiambas, Evangelos
    Lazaris, Andreas C.
    Saetta, Angeliki A.
    Karameris, Andreas
    Vilaras, George
    Patsouris, Efstratios
    [J]. JOURNAL OF BUON, 2014, 19 (01): : 109 - 114
  • [39] Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis
    Lee, CM
    Lee, RJ
    Hammond, E
    Tsodikov, A
    Dodson, M
    Zempolich, K
    Gaffney, DK
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 93 (01) : 209 - 214
  • [40] Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis?: Results of combined use of antibodies against different c-erbB2 protein domains
    Sapino, A
    Coccorullo, Z
    Cassoni, P
    Ghisolfi, G
    Gugliotta, P
    Bongiovanni, M
    Arisio, R
    Crafa, P
    Bussolati, G
    [J]. HISTOPATHOLOGY, 2003, 43 (04) : 354 - 362